Global Blood Therapeutics, Inc. (NASDAQ:GBT) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07

The following proposals were submitted to the stockholders at the
2017 Annual Meeting of Stockholders (the Annual Meeting) of
Global Blood Therapeutics, Inc. (the Company) held on June 20,
2017:

(i)The election of two ClassII directors, as nominated by the
Board of Directors, to hold office until the 2020 Annual Meeting
of Stockholders or until their successors are duly elected and
qualified; and

(ii)The ratification of the appointment of KPMG LLP as the
independent registered public accounting firm of the Company for
its fiscal year ending December31, 2017.

The proposals are described in detail in the Companys definitive
proxy statement for the Annual Meeting filed with the Securities
and Exchange Commission on April28, 2017.

The number of shares of common stock entitled to vote at the
Annual Meeting was 43,622,095. The number of shares of common
stock present or represented by valid proxy at the Annual Meeting
was 32,537,658. All matters submitted to a vote of the Companys
stockholders at the Annual Meeting were approved and all director
nominees were elected.

The number of votes cast for and against and the number of
abstentions and broker non-votes with respect to each matter
voted upon are set forth below:

There were 5,920,652 broker non-votes regarding the election of
directors.

The Companys stockholders ratified the appointment of KPMG LLP as
the Companys independent registered public accounting firm for
the fiscal year ending December31, 2017. The results of the
voting included 32,480,139 votes for, 45,660 votes against, and
11,859 votes abstained.

There were zero broker non-votes regarding this proposal.

About Global Blood Therapeutics, Inc. (NASDAQ:GBT)

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company’s segment is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. It is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD) and is evaluating GBT440 in SCD subjects in an ongoing Phase I/II clinical trial. SCD is a genetic disease marked by red blood cell (RBC) destruction and occluded blood flow and hypoxia, leading to anemia, stroke, multi-organ failure, severe pain crises, and shortened patient life span. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. It is also engaged in other research and development activities targeted towards hereditary angioedema (HAE).